Pioneering the Development of Automated Technologies for Cell-Based Therapeutics and Bioprocessing

For more than two decades ThermoGenesis Holdings, Inc. has developed and commercialized novel cell processing systems and devices providing global researchers, biomanufacturing organizations and clinicians with highly efficient cell processing devices which helped them to deliver better outcomes in various applications in the cell and gene therapy field.

Clinical BioBanking
With over 20 years of providing cord blood to banks hospitals, researchers and stem clinicians with systems designed to handle stem cells with the highest level of precision, safety, and confidence.
Point-of-Care Solutions
We develop products to obtain bone marrow concentrates easily, consistently, and reliably from bone marrow aspirates at the point-of-care with minimal red blood cell contamination.
Cellular Processing
The first step in the process is often the most important. That's why we have created closed-system novel and innovative technologies aimed at advancing cell therapies to the clinic.

Recent News

ThermoGenesis Holdings to Hold Reconvened Annual Meeting of Stockholders on January 13, 2022

RANCHO CORDOVA, Calif., January 11, 2022 — ThermoGenesis Holdings, Inc. (Nasdaq: THMO), today announced that the Company’s 2021 Annual Meeting of Stockholders (the “Annual Meeting”) will reconvene on Thursday, January 13, 2022 at 12:00 p.m. EST. The meeting, originally scheduled for December 16, 2021, was convened and adjourned without any business being conducted due to … Continued

ThermoGenesis Holdings to Present at the H.C. Wainwright BioConnect Virtual Conference

RANCHO CORDOVA, Calif., January 10, 2022 — ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced that Chief Financial Officer, Jeff Cauble, will present a company overview at the H.C. Wainwright BioConnect Virtual Conference taking place January 10-13, 2022. The … Continued

ThermoGenesis Holdings Announces Adjournment of Annual Meeting of Stockholders

RANCHO CORDOVA, Calif., December 17, 2021 — ThermoGenesis Holdings, Inc. (Nasdaq: THMO), announced that the Company’s Annual Meeting of Stockholders (the “Annual Meeting”) scheduled for Thursday, December 16, 2021 at 9:00 a.m. PST, was convened and adjourned without any business being conducted due to lack of the required quorum. A quorum consists of a majority … Continued

CGT CDMO: Controlled Cell Manufacturing Meets Controlled Smart Storage Solutions

Contract Development Manufacturing Organization (CDMO) partnerships are on the rise due to an increased demand for cell therapies and the limited availability of Good Manufacturing Practice (GMP) approved manufacturing facilities and other resources. Pharmaceutical & biotechnology companies are needing to outsource their product development and manufacturing in order to try to meet these demands, even … Continued

BACS: What to Consider When Sorting Cell Populations

    Cell separation is an essential part of the manufacturing process for CGT cell therapies like CAR-T. To get the best results, cell samples must be purified and prepared properly. Purifying cells is achieved by a different approaches (positive selection, negative selection, etc.) which all can use different methodologies to accomplish their goals. Some of the … Continued

Click below and be the first to hear about the latest news, breakthroughs, and products with the ThermoGenesis newsletter delivered directly to your inbox.
How may we help?